Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 8;14(3):592.
doi: 10.3390/pharmaceutics14030592.

Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy

Paula Bachmann  1 , Niklas Frahm  1 , Jane Louisa Debus  1 , Pegah Mashhadiakbar  1 , Silvan Elias Langhorst  1 , Barbara Streckenbach  1   2 , Julia Baldt  1   2 , Felicita Heidler  2 , Michael Hecker  1 , Uwe Klaus Zettl  1
Affiliations

Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy

Paula Bachmann et al. Pharmaceutics. .

Abstract

Polypharmacy (PP) is a common problem in modern medicine, especially known to affect patients with chronic diseases such as multiple sclerosis (MS). With an increasing number of drugs taken, the risk of potential drug-drug interactions (pDDIs) is rising. This study aims to assess the prevalence and clinical relevance of polypharmacy and pDDIs in patients with MS. Pharmacological data of 627 patients with MS were entered into two drug-drug-interaction databases to determine the number and severity of pDDIs for each patient. The patients were divided into those with and without PP (total PP and prescription medication PP (Rx PP)). Of the 627 patients included, 53.3% and 38.6% had total PP and Rx PP, respectively. On average, every patient took 5.3 drugs. Of all patients, 63.8% had at least one pDDI with a mean of 4.6 pDDIs per patient. Less than 4% of all pDDIs were moderately severe or severe. Medication schedules should be checked for inappropriate medication and for possible interacting drugs to prevent pDDIs. Physicians as well as pharmacists should be more sensitive towards the relevance of pDDIs and know how they can be detected and avoided.

Keywords: Rx drugs; clinical decision support software; drug–drug interactions; multiple sclerosis; over-the-counter drugs; polypharmacy.

PubMed Disclaimer

Conflict of interest statement

P.B., J.L.D., P.M., S.E.L., B.S., J.B. and F.H. declare no conflicts of interest. NF received travel funds for research meetings from Novartis. M.H. received speaking fees and travel funds from Bayer HealthCare, Biogen, Merck Serono, Novartis and Teva. U.K.Z. received speaking fees, travel support and/or financial support for research activities from Alexion, Almirall, Bayer, Biogen, Bristol-Myers-Squibb, Janssen, Merck Serono, Novartis, Octapharm, Roche, Sanofi Genzyme, Teva as well as EU, BMBF, BMWi and DFG.

Figures

Figure 1
Figure 1
Average number of pDDIs per patient with MS, stratified by PP status and type of PP. The patients were classified by PP status according to total PP (intake of at least five drugs of any kind) and Rx PP (intake of at least five drugs only available on prescription). Standard deviations are displayed as error bars. The average number of pDDIs was higher in PwP compared with Pw/oP, for both total PP (8.2 ± 9.7 versus 0.5 ± 1.0) and Rx PP (10.5 ± 10.4 versus 0.9 ± 1.4). MS—multiple sclerosis; pDDI—potential drug–drug interaction; PP—polypharmacy; PwP—patients with polypharmacy; Pw/oP—patients without polypharmacy; Rx—only available on prescription.
Figure 2
Figure 2
Distribution of severity levels of pDDIs in patients with MS. For the 627 patients, we recorded 2887 pDDIs in total (counted with repetitions) based on MediQ and Stockley’s drug interaction checker. MS—multiple sclerosis; pDDI—potential drug–drug interaction.
Figure 3
Figure 3
Proportion of patients with MS with at least one pDDI for each severity level and depending on the number of drugs used. The composite rating of pDDI severities was based on MediQ and Stockley’s drug interaction checker. Both prescription and over-the-counter drugs were considered for this plot. CI—confidence interval; MS—multiple sclerosis; pDDI—potential drug–drug interaction.
See this image and copyright information in PMC

References

    1. Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230. doi: 10.1186/s12877-017-0621-2. - DOI - PMC - PubMed
    1. Frahm N., Hecker M., Zettl U.K. Polypharmacy among patients with multiple sclerosis: A qualitative systematic review. Expert Opin. Drug Saf. 2020;19:139–145. doi: 10.1080/14740338.2020.1720646. - DOI - PubMed
    1. Payne R.A. The epidemiology of polypharmacy. Clin. Med. 2016;16:465–469. doi: 10.7861/clinmedicine.16-5-465. - DOI - PMC - PubMed
    1. Walton C., King R., Rechtman L., Kaye W., Leray E., Marrie R.A., Robertson N., La Rocca N., Uitdehaag B., van der Mei I., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. Houndmills Basingstoke Engl. 2020;26:1816–1821. doi: 10.1177/1352458520970841. - DOI - PMC - PubMed
    1. Filippi M., Bar-Or A., Piehl F., Preziosa P., Solari A., Vukusic S., Rocca M.A. Multiple sclerosis. Nat. Rev. Dis. Primer. 2018;4:43. doi: 10.1038/s41572-018-0041-4. - DOI - PubMed

LinkOut - more resources